A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage

被引:43
作者
Blok, VT
Daha, MR
Tijsma, OMH
Weissglas, MG
van den Broek, LJCM
Gorter, A
机构
[1] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Nephrol, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Urol, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1038/labinvest.3780038
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It is still unclear which membrane-bound regulatory proteins (mCRP) are important in vivo to protect tumor cells from complement-mediated damage. To address this question, the expression levels of CD46, CD55, and CD59 were measured semi-quantitatively in situ on renal cell carcinomas and compared with the expression level and cellular distribution of these mCRP in proximal tubuli within each patient (n = 31). It was also determined whether the expression of mCRP on tumor cells is associated with deposition of C3d and C5b-9. CD46 expression was decreased on tumor cells; in contrast, CD55 was expressed on tumor cells (12 out of 31 samples), while it was not detected on proximal tubular epithelial cells (PTEC). Also, expression of CD59 on tumor cells was increased as compared with its expression on PTEC. Furthermore, the localization on the cell surface of mCRP as observed on PTEC was altered on tumor cells. Because expression of mCRP may limit a complement-mediated anti-tumor response, we determined whether complement deposition was associated with the expression level of CD46, CD55, and CD59. The presence of C3d on tumor cells was associated with a low expression level of CD46 (p < 0.02). The expression level of CD46 was also associated with a low tumor stage lo (p < 0.04). The results suggest that in vivo CD46 plays a role in the protection of human renal tumor cells from complement-mediated injury.
引用
收藏
页码:335 / 344
页数:10
相关论文
共 40 条
  • [11] 2-H
  • [12] Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: Clinical results and immunologic correlates of response
    Bukowski, RM
    Olencki, T
    Wang, Q
    Peereboom, D
    Budd, GT
    Elson, P
    Sandstrom, K
    Tuason, L
    Rayman, P
    Tubbs, R
    McLain, D
    Klein, E
    Novick, A
    Finke, J
    [J]. JOURNAL OF IMMUNOTHERAPY, 1997, 20 (04) : 301 - 311
  • [13] DECAY-ACCELERATING FACTOR PROTECTS HUMAN-TUMOR CELLS FROM COMPLEMENT-MEDIATED CYTO-TOXICITY INVITRO
    CHEUNG, NKV
    WALTER, EI
    SMITHMENSAH, WH
    RATNOFF, WD
    TYKOCINSKI, ML
    MEDOF, ME
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (04) : 1122 - 1128
  • [14] CLAASEN HHV, 1992, LAB INVEST, V67, P166
  • [15] Devaux P, 1999, EUR J IMMUNOL, V29, P815
  • [16] ANTIBODIES AS CYTOTOXIC THERAPY
    DILLMAN, RO
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) : 1497 - 1515
  • [17] Renal cell carcinoma: Management of advanced disease
    Figlin, RA
    [J]. JOURNAL OF UROLOGY, 1999, 161 (02) : 381 - 386
  • [18] PROGNOSTIC-SIGNIFICANCE OF MORPHOLOGIC PARAMETERS IN RENAL-CELL CARCINOMA
    FUHRMAN, SA
    LASKY, LC
    LIMAS, C
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (07) : 655 - 663
  • [19] Immune evasion of tumor cells using membrane-bound complement regulatory proteins
    Gorter, A
    Meri, S
    [J]. IMMUNOLOGY TODAY, 1999, 20 (12): : 576 - 582
  • [20] Gorter A, 1996, LAB INVEST, V74, P1039